Unusual case of residual cortical lens matter in anterior chamber

Modern cataract surgery does not allow for any residual cortical matter in the anterior or posterior chamber, not even in the capsular bag. But for a beginner, a residual cortex in the eye is preferable to a ruptured posterior capsule and its associated complications. Therefore, the surgeon can stop and allow a minor complication (retained cortical material) to prevent posterior capsular rupture.

Case report

A 52-year-old female patient was operated for posterior subcapsular cataract in her right eye. Her left eye had previously gone into phthisis bulbii 5 years earlier; she underwent a 360° buckling with vitreoretinal surgery in her left eye for traumatic total retinal detachment 6 years earlier.

The surgery was performed by a resident eye surgeon who was in the learning stage of phacoemulsification. During cortical aspiration, the matter at the 12 o'clock position was proving difficult to handle for the surgeon. The surgeon therefore thought, in the best interest of the patient, that the amount of sub-incisional cortical matter (approximately 2 clock hours, extending up to the capsular-hexis margin towards the centre) would abate with time. He did not take any risk of further manipulations and getting a posterior capsular tear.

The surgeon increased the size of the corneal incision and implanted the all-PMMMA (Single-piece, Biconvex, Mod C Step Vault, from AI Optics Ltd, India) intraocular lens. (The patient could not afford any other lens and the above lens is available free of cost for deserving patients in our centre.) The wound was closed with 10/0 monofilament Nylon sutures.

The first postoperative day did not reveal any unusual inflammation. The eye was quiet on third postoperative day (first follow up). At second follow up (10th postoperative day), the operated eye revealed a white, fluffy mass (Fig 1) in the anterior chamber. This cotton-wool ball-like mass was diagnosed to be retained sub-incisional cortical lens matter based on normal anterior segment and fundus findings. The IOP was 28 mm Hg in her right eye. Because of the raised IOP and the one-eyed status of the patient, immediate removal of cortical lens matter was planned. The side port was used to aspirate cortical matter with topical 0.5% oxybuprocaine (proparacaine) eye drops, using a 23 gauge canula. Postoperatively there was normalisation (off oral medications) of raised IOP within 48 hours. All sutures were removed after 6 weeks (Fig 2). The final best corrected visual acuity was 6/6.

Comment

The case is reported to highlight the importance of complete removal of cortical matter. The reason for difficulty in aspirating sub-incisional cortex in our case was inferiorly decentralised capsulorhexis and corneal oedema at the incision site. Other reasons that can hamper the removal of such cortex could be positive vitreous pressure, long tunnel, fluid leakage due to divarication of incision lips, small capsulorhexis, probable miosis and corneal folds. The raised IOP in our case could be due to obstruction of trabecular meshwork by lens debris and inflammatory components in the form of heavy-molecular-weight soluble lens proteins. The did not receive any public or private support.

References


Case 1

A 45-year-old male patient presented with progressive bilateral blurred vision and floaters 10 months post-BMT for CML. He had no history of ocular disease. His symptoms started 10 days after discontinuation of cyclosporin A as a routine protocol and were accompanied by alopecia, poliosis, vitiligo, and oral mucositis. A presumptive diagnosis of acute GVHD was made and cyclosporin restarted together with prednisolone. His other medications were azathioprine, aciclovir, flucytosine, and ranitidine.

Best corrected visual acuity was 6/9 bilaterally, with no afferent pupillary defect. There was no evidence of inflammation in anterior segments or vitreous and normal intraocular pressures. There was mild disc pallor with swelling and surrounding radial choroidal folds and several pale subretinal perifoveal lesions on the left. Systemic examination revealed widespread patchy alopecia with poliosis, vitiligo of the arms, and mild oral mucositis. Fluorescein angiography showed mild dilatation of the disc capillaries and extensive focal leakage from the retinal pigment epithelium, but no evidence of cystoid macular oedema. Ultra-
sonography showed a thickened posterior sclera. Optical coherence topography (OCT) showed subretinal fluid bilaterally. Cerebral magnetic resonance imaging (MRI) and lumbar puncture revealed no abnormalities.

The clinical appearances were consistent with posterior scleritis together with a diffuse retinal pigment epitheliopathy. A reducing regimen of high dose steroids in combination with acetazolamide resulted in clinical improvement and visual stabilisation.

Case 2
A 31 year old white female underwent total body irradiation and BMT for γδ T cell splenic lymphoma. One month later she developed acute GVHD related erosive enteropathy resulting in life threatening exsanguination. Following successful resuscitation (which precipitated admission to intensive care for 6 weeks), she noted blurred left eye vision and described difficulty in dark adaptation and differentiating between shades of grey; there was right strabismic amblyopia. The patient’s medication comprised aciclovir, cyclosporin, penicillin, propranolol, and lansoprazole.

Visual acuity was 6/18 and N14 with the right eye, and 6/12 and N5 with the left. Colour vision was normal and visual fields were full. There was no afferent pupillary defect. The anterior chambers and vitreous were quiet. The optic discs were normal. At both maculas (Fig 1), there were deep subretinal cream coloured spots and retinal thickening and OCT evidence of subretinal fluid without cystoid changes. Fluorescein angiography showed a few hyperfluorescent spots consistent with focal retinal pigment epithelium dysfunction. Electrodiagnostic tests identified diffuse rod dysfunction.

Since there was biochemical evidence of renal impairment, acetazolamide was considered to be contraindicated to treat the subretinal fluid. By 4 months, the best corrected visual acuities were 6/12 and 6/12+2 left. Repeat electrophysiology was unchanged, however by ten months the full field electroretinograms had improved to normal limits.

Comment
GVHD is presumed to be caused by donor T lymphocytes recognising minor histocompatibility antigens on recipient tissues that are then subjected to CD8-T lymphocyte mediated attack. Commonly reported ocular manifestations include pseudomembranous conjunctivitis, keratoconjunctivitis sicca, corneal epitheliopathy, and cataract.1 Posterior segment involvement is rare and includes cotton wool spots2 as well as central serous choriotretnopathy.3

In both of our cases, there seems to be a striking temporal association between the onset of visual symptoms and an adverse event in the course of the disease. In case 1, in whom the cessation of cyclosporin resulted in acute GVHD, the ocular findings were consistent with scleritis, a feature only once previously reported.4 Postmortem studies have demonstrated choroidal infiltrates in GVHD patients containing histiocytelike large eosinophils5 and clinically these may be represented by the pale perifoveal lesions observed in the left eye. Subsequently this patient was shown to be HLA-DR4 positive, a finding common in individuals with Harada’s disease and frequently associated with chronic GVHD.6

By contrast, the ocular findings in the second case were not a result of acute but a consequence of previous life threatening GVHD during which exsanguination occurred. While interruption of blood flow to the optic nerve or visual cortex can account for visual loss following extreme haemorrhage, retinal ischaemia has also been documented.7 The rod photoreceptor system appears most vulnerable,8 a feature consis-

Figure 1 Images of case 2 (in each case right eye on the right). (A) Colour fundal photographs at presentation, showing deep subretinal cream coloured spots and overlying retinal thickening. (B) Optical coherence tomography of each macula (foveae arrowed) at presentation showing evidence of subretinal fluid without cystoid changes. (C) Fluorescein angiography (later arteriovenous phase) at presentation showing a few hyperfluorescent spots consistent with focal RPE dysfunction. (D) Colour fundal photographs 4 months later showing irregular pigmentation at the level of the retinal pigment epithelium.
tent with the electrophysiological findings in this case, and the patient’s difficulty with dark adaptation is in keeping with rod dysfunction. Of interest was the subsequent improvement in acuity and electrophysiological responses. Such a pattern parallels electrophysiological studies of children after respiratory or circulatory arrest where initially subnormal ERG responses return to normal levels within 8 months. The mechanism that mediates this recovery is not known.

Graft versus host disease is a common complication of bone marrow transplantation that usually presents to the ophthalmologist with anterior segment signs. However, GVHD may also present with posterior segment presentations of the types described here.

N G Strouthidis, P J Francis, M R Stanford, E M Graham
The Medical Eye Unit, 9th Floor, North Wing, St Thomas’s Hospital, Lambeth Palace Road, London SE1 7EH, UK

N G Strouthidis, P J Francis, G E Holder, A C Bird
Moorfields Eye Hospital, 162 City Road, London EC1V 2PD, UK

Correspondence to: Dr E M Graham, The Medical Eye Unit, 9th Floor, North Wing, St Thomas’s Hospital, Lambeth Palace Road, London SE1 7EH, UK; nicholas.strouthidis@btinternet.com

Accepted for publication 25 February 2003

References

Anterior pathway vision loss due to subdural haematoma

Patients with vision loss associated with subdural haematomas typically present with homonymous hemianopias secondary to compression of the posterior cerebral artery during trans-tentorial herniation. In these cases, necropsy studies have demonstrated pregeniculate involvement in addition to occipital lobe lesions. We present a case illustrating a rarely reported phenomenon of anterior pathway vision loss associated with a subdural haematoma without any evidence of optic disc swelling, occipital lobe disease, or radiographic signs of chiasmal or optic nerve compression.

Case report
A 51 year old man, who had previously undergone two craniotomies (October 1992 and November 2000) for resection of an epidermoid tumour at the cerebellopontine angle, developed hydrocephalus and had a

Figure 1 Fundus photograph with right (A) and left (B) optic nerves without oedema or pallor on initial presentation. Humphrey visual fields (C) on presentation and (D) 6 months following craniotomy with decompression of the subdural haematoma.
Magnetic resonance imaging (MRI) of the brain showed that the right subdural haematoma was still present but was decreased in size to 2.1 cm on coronal section (Fig 2A) compared to the study performed 1 month earlier. No intraorbital abnormalities were present, and the optic nerves and chiasm appeared free of direct compression by the haematoma. The blood did not appear to surround the optic nerves (Fig 2B). The patient’s haematocrit and blood pressure remained within normal limits during the initial presentation and subsequent treatment. The patient underwent craniotomy with further drainage of the subdural haematoma. After 6 months, the patient’s vision in the left eye improved to 20/200. Follow up perimetry showed less constriction on the right and improved performance on the left (Fig 1D). Funduscopic examination revealed mild optic nerve pallor in the left eye and a normal appearing right optic nerve.

Comment
This case represents a rare example of anterior pathway vision loss due to subdural haematoma. Most cases of vision loss with subdural haematoma affect the posterior visual pathway, with mechanisms including occipital infarct and compression of the posterior cerebral artery during trans-tentorial herniation. Posterior lesions may present with anterior signs—for example, optic atrophy was seen in three patients with occipital infarcts, two of whom initially presented with severe disc oedema. Necropsy studies have shown that trans-tentorial herniation can result in damage at the level of the optic tract, chiasm, or optic nerves.

The anterior visual pathway can be compromised directly by gyrus herniation into the suprasellar cistern, a mechanism associated with meningiomas. Prechiasmal vision loss due to intracranial optic nerve infarction has also been reported in the setting of subdural haematoma; in this case the mechanism was presumably due to direct compression of the nerve against basilar skull structures, although this specific radiographic finding was not described.

The precise mechanism of anterior pathway vision loss due to subdural haematoma in our patient, as well as in the few previous reports, remains poorly understood. MRI showed no signs of blood in the orbits, direct compression of the optic nerves or chiasm, or gyrus herniation into the suprasellar cistern. The occipital lobes also appeared normal. Right to left midline shift due to the right sided haematoma was present, probably leading to vascular compromise or nerve compression that could not be visualised on MRI. Visual improvement following chiasmal decompression of mass lesions has been reported, and this mechanism may explain our patient’s improved visual acuity and peripheral fields following the drainage of the haematoma. Surprisingly, the subdural haematoma in our patient was smaller at the time of onset of visual symptoms than it had been 1 month earlier.

Subdural haematomas can affect vision through compression or vascular compromise at many points along the visual pathway. This case illustrates that optic neuropathy can occur late in the setting of a subdural haematoma, after the volume of the haematoma has begun to decrease because of the many ways in which patients with subdural haematomas can lose vision, they require close follow up, and a sudden change in vision necessitates immediate radiological testing, ophthalmological examination and, probably, urgent surgical intervention and drainage.

References

Surodex in paediatric cataract surgery
Paediatric cataract surgery is associated with a high incidence of postoperative inflammation.1–9 Intensive topical steroid therapy is still relied upon as the conventional mode of prevention and treatment.1,2 Frequently, adjuvant systemic10 and/or periocular steroids11 may be required for further control, particularly if the child has a history of, or is at risk of, uveitis (for example, microphthalmos).12 Non-compliance and missed application of steroid drops into the eye impedes control of the postoperative uveitis.

The Oculux Drug Delivery System (DDS; Oculux Pharmaceuticals, Inc, Sunnyvale, CA, USA) is a biodegradable device that allows sustained drug release after insertion into the anterior chamber (AC). Surodex is a DDS with 60 μg of dexamethasone incorporated into the polymer matrix (poly(lactic-glycolic)-acid, PLGA) with sustained and controlled release of dexamethasone over 7 days, achieving higher intraocular drug levels than with conventional dexamethasone eye drops.13 Randomised controlled trials found Surodex to be as effective as 0.1% dexamethasone eye drops in the control of postcataract surgery inflammation.14–15 Surodex is approved for use in cataract surgery in Singapore.

We reviewed retrospectively all paediatric patients who underwent cataract surgery with the insertion of one pellet of Surodex into the AC at the conclusion of surgery. Eighteen eyes of 13 patients (nine males and four females) were diagnosed with cataracts at a mean age of 57.4 months (range 1 day to 136 months). The mean age at surgery was 66.3 months (range 1 week to 139 months) and follow up period ranged from 6–18 months (mean 7.8 months). Factors predisposing to cataracts included hereditary cataracts (two), microphthalmos (three),
severe atopic dermatitis (one) and traumatic cataract (one). The types of cataract included total/mature (seven), nuclear (two), lamellar (three), subcapsular (two), posterior lenticu-

nus (two), and posterior polar (two).

All eyes underwent lens aspiration through can open anterior capsulotomy or continu-

ous curvilinear capsulorhexis (CCC) under general anaesthesia. Fourteen eyes had either posterior capsulotomy (with the vitrectomy cutter) or a posterior CCC (surgeon’s pre-

ference). Anterior vitrectomy was done in 13 eyes. Eleven eyes (61.1%) were implanted with a foldable intraocular lens (IOL) (Acrysof lens MA60BM, 10 and MA30BM, 1) (pseudophakic group) (Table 1). This group was older (mean 84.81 months) than the aphakic group (mean age 14.31 months). Only seven eyes (63.6%) of the pseudophakic group underwent posterior CCC/capsulotomy and anterior vitrectomy, compared to all eyes in the aphakic group. Complications were en countered in four eyes in the pseudophakic group (36.4%)—malposition of IOL, vitreous strand in AC, posterior synechiae and raised IOP.

Four eyes (two in the pseudophakic and two in the aphakic group) did not receive additional postoperative topical steroids (predni-

solone acetate 1%). This decision was made for patients 4 and 12 as there was minimal manipulation and iris trauma intraoperatively. These children were older (ages 131 and 115 months at surgery), allowing for easier follow up examination. Patient 15 had developmental delay and was difficult to manage. All four eyes were assessed to be quiet by slit lamp examination 2–4 weeks postoperatively. Additional ster-

oids were not indicated and there was no

glaucomatous cup-

nous inflammation in the first week. The left eye of patient 6, which had been quiescent 2–4 weeks postoperatively. Additional ster-

oids were not indicated and there was no

inflammation, the steroid eye drops were stopped after 3 weeks. This eye achieved a final visual acuity of 20/20.

Fibrinous anterior uveitis is common after paediatric cataract surgery, occurring in varying severities in up to 10% of cases. In

our series, only two eyes (11.1%) developed inflammation that required addi-
tional steroid therapy. The remaining 16 eyes achieved good control of inflammation, par-

ticularly the three eyes that received Surodex without postoperative topical steroids. None experienced rebound uveitis after 1 week, when the pellet had ceased its release of dexamethasone. This suggests that in selected eyes, a Surodex pellet alone may be adequate to control postoperative inflammation. A randomised controlled trial comparing Surodex versus conventional steroid eye drop therapy will be needed to determine the ultimate efficacy of Surodex in paediatric eyes.

Comment

The efficacy of eye drops is dependent on compliance and timely application for drug penetration and absorption. In infants and young children, the systemic absorption of the steroid may have potentially serious complications such as hyperglycaemia and immunosuppression. Surodex significantly reduces the total dose required, as the 60 µg of dexamethasone in one pellet is approximately equivalent to that in just one droplet of 0.1% dexamethasone. A system such as the DDS allows for direct application of the drug to the target site, potentially eliminating the problems of compliance. The single complication encountered, which may be related to Surodex insertion, is the late onset of raised IOP (patient 6) despite the lack of marked postoperative inflammation. The fellow eye had also under-
gone cataract surgery with insertion of Surodex without complications. Steroid responsive glaucoma is an unlikely cause as the drug has been shown to persist only for 7 days in rabbits, although this has not been demonstrated in human eyes. Gonioscopy may reveal focal peripheral anterior syne-

chiae (PAS) at the site of residual pellet, but it is unlikely that this minor degree of synechiae may cause angle closure glaucoma, although the pellet may persist for weeks in the angles. Unfortunately, gonioscopy was not performed in this eye. Glaucoma after paediatric cataract surgery is, however, a complication that increases in frequency with longer durations of follow up (3–22%).

We acknowledge that there are several limitations to these findings. Firstly, being a retrospective review, the efficacy of Surodex in preventing postoperative capsular opacification, an indicator of postoperative inflammation, could not be assessed. We are also unable to establish if Surodex alone is sufficient for postoperative control of inflammation, this would require a prospective randomised clinical controlled trial. The efficacy of control of postoperative inflammation and safety are incomplete without the assessment of flare and endothelial cell counts but these are difficult in children, although endothelial cell count studies in adult eyes have shown no significant change. Finally, gonioscopy to visualise the angles to look for PAS was also not done.

Surodex has previously been shown to be safe and effective in uncomplicated cataract surgery in adults. This retrospective review provides preliminary data to suggest that Surodex may be an effective and safe adjunctive anti-inflammatory agent that in some paediatric eyes may eliminate the need for other steroid administration. Further studies will be required to determine the ultimate safety of Surodex in paediatric eyes.

Table 1  Pseudophakic and aphakic groups

<table>
<thead>
<tr>
<th></th>
<th>Pseudophagic group</th>
<th>Aphakic group</th>
</tr>
</thead>
<tbody>
<tr>
<td>No of eyes</td>
<td>11 (61.1%)</td>
<td>7 (38.9%)</td>
</tr>
<tr>
<td>Mean age at surgery</td>
<td>84.8 months</td>
<td>14.3 months</td>
</tr>
<tr>
<td>No of eyes with posterior capsular opening and anterior vitrectomy</td>
<td>7 (63.6%)</td>
<td>7 (100%)</td>
</tr>
<tr>
<td>No of eyes with intact posterior capsule complications</td>
<td>4 (36.4%)</td>
<td>0</td>
</tr>
<tr>
<td>Intraoperative complications</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Postoperative complications</td>
<td>4 (36.4%)</td>
<td>1 (14.3%)</td>
</tr>
<tr>
<td>1 Malposition of PCIOL</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>2 Vitreous strand in anterior chamber with peaked pupil</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>3 Posterior synechiae</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>4 Fibrinous inflammation</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>5 Raised intraocular pressure</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

References


Pars plana ciliary epithelial proliferation in 13q deletion syndrome

The 13q deletion syndrome is an uncommon chromosomal disorder affecting the long arm of chromosome 13 which is deleted to a variable degree. This syndrome is phenotypically characterized by mental retardation, structural malformations, facial dysmorphism, and a predisposition to develop retinoblastoma. This intraocular tumour is diagnosed in approximately 80% of cases with this syndrome. Moreover, the incidence of bilateral retinoblastoma is much higher in individuals with this syndrome. The retinoblastoma susceptibility gene (RB-1), which encodes for the nuclear phosphoprotein of 105 kDa, is located in band 13q14. The involvement of the q14 band on the long arm of chromosome 13 places patients with this syndrome at significant risk for developing retinoblastoma. In addition, children with 13q deletion syndrome also show optic nerve hypoplasia and retinal dysplasia. In this case, we report additional findings of pars plana ciliary epithelial proliferation in 13q deletion syndrome.

Case report

A 5 month old Hispanic female infant with a karyotype 46,XX, del (13)(q14.1q21.3) was referred to us for the evaluation of retinoblastoma. She had dysmorphic features, such as craniostenosis. There was no family history of ocular or systemic disease. While under anesthesia, the patient’s right eye was examined, revealing a mass that occupied a large area of the inferior nasal portion of the retina. Under anaesthesia, the patient’s right eye was examined, revealing a mass that occupied a large area of the inferior nasal portion of the retina.

Figure 1

The retinoblastoma shows numerous Flexner-Wintersteiner and Homer Wright rosettes (haematoxylin and eosin; original magnification ×200). Inset; note a large endophytic retinoblastoma arising from the inferior retina and obscuring the optic disc. (Fig 1). There was no tumour invasion of the uvea or the posterior optic nerve. In addition, the globe exhibited a multilayered plaqueloid non-pigmented ciliary epithelial proliferation at the pars plana ciliars (Fig 2) and optic nerve hypoplasia. The epithelial proliferation revealed benign histological features, unlike the malignant neoplastic proliferation of the retina. At the pars plana ciliars, the pigment epithelium showed focal proliferation.

Comment

The extent of the deletions affecting the long arm of chromosome 13 may result in various developmental anomalies that constitute 13q syndrome. Proliferation of the pars plana ciliars non-pigmented ciliary epithelium, as noted in the present case, and its association with retinoblastoma suggests that the RB-1 gene, or a gene close to the RB-1 locus may have a role in the proliferation of the other neuroepithelial structures of the eye, including the pars plana ciliary epithelium.

In embryological terms, the non-pigmented ciliary epithelium is derived from the inner layer of the optic cup which also gives rise to the neural retina. Proliferation of the pars plana ciliary epithelium in an eye that harbours retinoblastoma suggests that the RB-1 gene may play a part in such epithelial proliferation. However, this epithelial proliferation has not been previously reported in eyes with retinoblastoma. Although the cause of proliferation of the ciliary epithelium is not clear, this case suggests that the non-pigmented ciliary epithelial proliferation at the pars plana ciliars in an eye that harbours retinoblastoma may be related to 13q deletion syndrome. Such findings may be unique to this syndrome, but previous reports about it have not mentioned them. The lack of previously reported cases with findings of pars plana epithelial proliferation suggests that this syndrome may have variable phenotypic expression.

Acknowledgements

This work was supported in part by NEI core grant EY03040 and by an unrestricted grant from Research to Prevent Blindness Inc, New York, USA. The clinical illustration is provided by Dr Linn A Murphree.

Y Uusi
Department of Ophthalmology, Tokyo Medical University, Tokyo, Japan

Y Uusi, N A Rao
The A Ray Irvine Ocular Pathology Laboratory, the Doheny Eye Institute, and the Department of Ophthalmology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA

Correspondence to: Yoshihiko Uusi, MD, Department of Ophthalmology, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan; usuyoshi@aol.com

References


Phacoencapsulation of posterior polar cataracts—a surgical challenge

Posterior polar cataracts are relatively uncommon yet they pose a significant chal-

Figure 2

(A) Low magnification of ciliary body and pars plana ciliars reveals plaqueloid thickening of non-pigmented ciliary epithelium and double layered pigment epithelium (haematoxylin and eosin; original magnification ×50). (B) High magnification of the pars plana ciliars shows multilayered proliferation of non-pigmented ciliary epithelium (haematoxylin and eosin; original magnification ×400).
Morphology

Posterior polar cataracts are associated with remnants of the hyaloid system or the tunica vasculosa lentis. These cataracts may also occur without any relation to hyaloid remnants and appear as circular or rosette shaped opacities; they are hereditary and usually transmitted as a dominant trait. The gene for this has been mapped to chromosome 16q22.7

Classification
See Table 1 and Figure 1.

Methods

The incidence of posterior polar cataracts in our centre is approximately 3 per 1000. We conducted a retrospective review from 1994 to 1999 and identified 31 patients (36 eyes) who had surgery for posterior polar cataracts.

Results

Four eyes had PCR (11.1%) and the other 32 had uncomplicated surgery; 34 eyes achieved a best corrected visual acuity of 6/12 or better (94.4%).

Comment

Our series showed a PCR rate of 11.1% in contrast with the 26% incidence reported by Osher et al and 36% by Vasavada and Singh. No hydrodissection was attempted and only careful controlled hydrodelineation was performed. This was done using small aliquots of balance salt solution (BSS) to loosen the nucleus while simultaneously watching the capsular bag to ensure that the fluid wave passed gently. In some cases, no hydroprocedures were necessary as there was slow separation of the nucleus by the BSS flowing from the phaco tip.

Vasavada and Singh described the use of step by step chop in situ and lateral separa-
tion to minimise stress on the capsule-zonule complex.7 We preferred the use of the “lambda” technique which involved sculpting in the shape of the Greek letter (λ), followed by cracking along both “arms” and removal of the central piece first. The advantage of this is its gentleness in not stretching the capsule while removing the quadrants, especially the first one. We emphasise that this is our preferred technique and other techniques would be equally effective in skilled hands.

We also used low vacuum, low aspiration, and low inflow parameters to ensure a more stable anterior chamber; bottle height was at 50 cm, vacuum at 100 mm Hg, and aspiration flow rate at 20 ml per minute. Optimum power setting was achieved when minimal movement of the nucleus occurred while sculpting.

The epinucleus and cortex were removed using manual dry aspiration with Simeone cannula. This method is gentler as we believe that the aspiration pressure is more controllable with our “million dollar” hands. There is also no “after aspiration” effect which in the automated unit can continue for several milliseconds even after the foot has been taken off the pedal. The disadvantage of manual aspiration is the increased surgical time.

The status of the posterior capsule (PC) dictated the action of the surgeon. If the PC was absent or torn but with no vitreous loss, a dispersive viscoelastic was injected over the defect to tamponade and push the vitreous face backwards. A dispersive rather than a cohesive viscoelastic is preferable as it is more adapted to maintaining a space and stabilising the anterior vitreous face. If there was PCR with vitreous loss, a two port anterior vitrectomy was performed. Intraocular lens implantation in these cases would depend on the extent of the PCR and the integrity of the remaining PC.

Surgical management of posterior polar cataracts poses a special challenge to the cataract surgeon. It is important that the surgeon and the patient understand the technical difficulties associated and are aware of potential complications. It may be prudent to address these cases at the end of an operating list or to shorten the list in anticipation of prolonged surgical time. The surgeon should use a technique that he or she is most familiar and comfortable with. With emphasis on gentleness, together with patience and a well practised technique, the incidence of PCR can be minimised in phacoemulsification for posterior polar cataracts.

M W Lee, Y C Lee
Lee Eye Centre, 44–46 Persiaran Greenhill, Ipoh,
Perak, 30450, Malaysia

Correspondence to: Dr Mun W Lee, Lee Eye Centre,
56 Hayscroft Road, Willington, Manchester M20
4XF, UK; bigmun@doctors.org.uk

Accepted for publication 3 March 2003

References

1 Luntz MH. Clinical types of cataracts. Duane’s Ophthalmology 1996;CD ROM.

Molluscum contagiosum in an immune reconstituted AIDS patient

In spite of lower viral loads and increasing T cell counts, AIDS patients receiving highly active antiretroviral therapy (HAART) are not always successful in mounting an immune response to some opportunistic pathogens. In fact, CMV reinitis, which was known to occur in HIV patients with CD4 counts below 50 ×10^9/L, has been described in immune reconstituted patients with CD4 counts above 200 × 10^9/L. It is therefore important to make observations about the clinical spectrum of infectious disease in immune reconstituted AIDS patients. Here we report an isolated

![Figure 1](A) One spot polar cataract. (B) Onion polar cataract. (C) Polar cataract with hole in posterior capsule. (D) Polar cataract with nuclear sclerosis.)
lesion of molluscum contagiosum in an immune reconstituted AIDS patient.

Case report

A 46 year old Hispanic female presented with a history of burning, tearing, and itching of her left eye for 1 month. Three years earlier she had been diagnosed with AIDS during a hospital admission for Pneumocystis carinii pneumonia (PCP). At that time her CD4 count had been 27 × 10⁶/l and her viral load 905 000. After 3 months of HAART her CD4 count had dropped to 15 000 and her viral load to 184 × 10⁶/l. Her viral load became undetectable 6 months after initiation of therapy and has remained so for 2½ years. Her recent CD4 count was 435 × 10⁶/l.

Best corrected visual acuity was 20/25 in each eye. A 2 mm smooth, dome-shaped, translucent papule with central umbilication was present inferior to the medial aspect of the left lower lid margin (Fig 1). The lesion was excised and histopathology revealed the number of molluscum contagiosum to be an inverse relation of the CD4 count and the number of molluscum contagiosum lesions.

The present case shows that the patient’s reconstituted immune system from HAART can limit molluscum contagiosum infection to a single lesion at the eyelid, clinically and histologically identical to molluscum contagiosum lesions found in immunocompetent hosts. Such limited expression of molluscum contagiosum could be from a competent T cell response as noted in individuals with normal immune function or those with reconstituted immune response from HAART. Thus, clinically the presence of a solitary molluscum contagiosum lesion in an HIV infected individual suggests appropriate response to HAART.

References


Malignant melanoma of the conjunctiva metastasising to the parotid gland

Conjunctival melanoma is rare, accounting for just 2% of ocular malignancies. We present an unusual case of conjunctival melanoma with subsequent metastasis to the parotid gland. A diagnosis was made after fine needle aspiration cytology of the parotid gland was performed in light of the previous history.

Figure 1. Note solitary umbilicated lesion involving lower eyelid margin.

Figure 2. Histologically, the molluscum contagiosum shows intracellular eosinophilic inclusion bodies (haematoxylin and eosin ×120).

Figure 2. Malignant melanoma of the conjunctiva metastasising to the parotid gland.

Conjunctival melanoma is rare, accounting for just 2% of ocular malignancies. We present an unusual case of conjunctival melanoma with subsequent metastasis to the parotid gland. A diagnosis was made after fine needle aspiration cytology of the parotid gland was performed in light of the previous history.

Case report

A 79 year old white man presented to the eye clinic in September 1999. He had been noted 3 years previously to have a small inclusion cyst of the bulbar conjunctiva in his right eye, which he complained had increased in size and was becoming red and sore. Examination showed an inflamed pedunculated lesion 1 cm in diameter arising from the nasal limbal conjunctiva (Fig 1). The lesion was granulomatous and amelanotic. There was adjacent corneal opacity. Ocular examination was otherwise unremarkable.

The appearance of the lesion was felt to be unusual with a presumptive diagnosis of conjunctival malignancy. Excision biopsy with conjunctival autografting was performed.

Histology revealed a primary nodular malignant melanoma, at least 7 mm thick, composed of epithelioid sparsely pigmented melanocytes positive for S100 and vimentin immunostains. Excision was deemed incomplete.

The patient was referred for adjuvant treatment with cryotherapy. To date, there has been no sign of local recurrence.

In June 2001, the patient was referred by his general practitioner to the oral surgery service at the same hospital with a 6 month history of pain on the right side of his neck. He had also noticed some right facial swelling. Clinical examination disclosed a diffuse, firm mass over the lower pole of his right parotid gland, measuring 4 cm in diameter. There were no overlying skin changes.

Magnetic resonance imaging (MRI) of the head and neck showed a well defined lesion within the right parotid gland involving the deep lobe and the deeper portion of the...
superficial lobe. A few small lymph nodes were visible at several sites bilaterally but none appeared enlarged. Computed tomography (CT) of the chest, abdomen and pelvis revealed single nodules measuring 3–5 mm at both lung bases, which may represent lung metastases.

An orthopantomogram was normal, and fine needle aspiration (FNA) cytology was performed. This showed scattered lymphocytes and highly pleomorphic non-lymphoid malignant cells, some containing flecks of pigment (Fig 2). While these appearances alone would not allow definitive diagnosis of melanoma, in the clinical context they were sufficient to conclude that the parotid swelling was likely to be metastatic melanoma. This was confirmed on subsequent parotid excision biopsy, which revealed extensive involvement of the parotid nodes and parotid parenchyma, extending into the external jugular vein.

Comment

Malignant melanoma is a relatively rare tumour in the parotid gland, with most tumours representing metastasis from cutaneous head and neck primaries. Very occasionally, as in this case, the primary tumour is non-cutaneous in origin.

 Conjunctival melanoma metastasising to the parotid has been noted in previous series, but remains rare. This case is unusual with respect to the initial size and appearance of the tumour, the previous history of a conjunctival cyt, and that definitive diagnosis of a metastatic lesion from a conjunctival primary was made by FNA. This method has been helpful in the diagnosis of other types of tumour in the parotid, and indeed in parotid melanomas of different origin. In this case, the patient’s previous ophthalmic history had been unknown to the maxillofacial surgeon managing the case, and the diagnosis only became clear during reporting of the cytology, when the FNA findings could be compared with previous histology. This illustrates the importance of exhaustive history taking and the value of a cohesive local histopathology service.

F Cuthbertson
Department of Ophthalmology, St James’s University Hospital, Beckett Street, Leeds LS9 7TF, UK

J Luck, S Rose
Royal United Hospital, Combe Park, Bath BA1 3NG, UK

Correspondence to: Dr Fiona Cuthbertson, Department of Ophthalmology, St James’s University Hospital, Beckett Street, Leeds LS9 7TF, UK; fcuthbertson@hotmail.com

Accepted for publication 26 March 2003

References


Bilateral Aspergillus endophthalmitis in a patient with chronic lymphocytic leukaemia

Aspergillus species are ubiquitous saprophytic moulds, commonly growing in soil, stored hay, and decaying vegetation. Even though exposure to Aspergillus is universal, infection in humans is uncommon. Aspergillus infection of ophthalmic interest usually causes keratitis or orbital cellulitis. Aspergillus endophthalmitis is a relatively rare condition that has a devastating course, with blindness as its usual outcome. The clinical diagnosis is difficult and the treatment is disappointing. In most cases, ocular involvement results from spread of aspergillus infection from organs and typically occurs in injecting drug users and in patients with immune deficiency of various causes. The leucopenia appears to be a predisposing condition for the occurrence of aspergillus.

We report an unusual case of bilateral endogenous Aspergillus endophthalmitis in a patient with chronic lymphocytic leukaemia in the absence of any detectable focus of aspergillus infection elsewhere in the body and that showed a good response to systemic therapy.

Case report

A 51 year old white man with a previous diagnosis of chronic lymphocytic leukaemia and use of an immunosuppressive agent was referred to ophthalmological examination because of a red eye, pain, and blurred vision in his right eye. The clinical picture worsened and diagnosis of endophthalmitis was made. Intravenous amphotericin B injection was performed and did not control the case. Culture of vitreous fluid was positive for Candida. This eye was eviscerated because of increasing pain, progressive infection, and poor response to treatment. Posterior histopathological study was conclusive for Aspergillus endophthalmitis in the right eye (Fig 1B and 2). At the same time, fundus examination of the left eye showed two subretinal exudative lesion located at nasal and inferior retina with retinal oedema associated with superficial haemorrhages (Fig 1A). The vitreous was clean and the central macula remained intact. Visual acuity was 6/6 in this eye.

Vitreous biopsy or culture may yield negative results in some cases of early intraocular Aspergillus endophthalmitis. We did not take a vitreous biopsy of the left eye, since we already had the diagnosis in the right eye and the visual acuity was 6/6. This eye was treated with intravenous amphotericin B and oral itraconazole with a good result. The patient remained stable with resolution of the lesions and no focus of systemic aspergillosis was found.

Comment

Fungal endophthalmitis is uncommon. In most of the cases Candida is the causal organism. Few cases of Aspergillus endophthalmitis in a patient with chronic lymphocytic leukaemia have been described, and according to the literature endogenous Aspergillus endophthalmitis represents a manifestation of disseminated aspergillosis, usually a fatal infection. This case is unusual because it is bilateral and no focus of systemic aspergillosis was found. The cases of intraocular inflammation secondary to Aspergillus are more common in the central macula and have a poor prognosis. In our case the localisation of the choroiditis in the left eye was out of the posterior area and the patient’s visual acuity remained 6/6.

The major antifungal agent used in aspergillosis is amphotericin B. Without host immune competence, treatment is rarely effective. Penetration of intravenous amphotericin B into the vitreous cavity of the normal or inflamed eye is poor. The azole compounds have been used to reduce the significant toxicity and enhance the efficacy...
of intravenous amphotericin B; oral fluconazole is the drug of choice because it has excellent penetration in central nervous system and vitreous. Itraconazole may be used. Intravitreous amphotericin B and vitrectomy have given the best results in the treatment of these cases. Our patient received intravenous amphotericin B and oral itraconazole and this therapy was sufficient to control the infection.

This case shows that Aspergillus endophthalmitis should be considered in all patients with immune deficiency even in the absence of systemic aspergillosis. Treatment with intravitreous amphotericin B may be able to control these cases and should be attempted more often.

D de O Machado, R Gonçalves, E M Fernandes, W R Campos, F Orefice
Department of Ophthalmology, Federal University of Minas Gerais, Brazil

A L L Curi
Department of Ophthalmology, Federal Fluminense University Niterói, Brazil

Correspondence to: André L L Curi, R Francisco Dutra 163/701, Icarai, Niterói, RJ, Brazil Cep 24220150; curial@yahoo.com

Accepted for publication 30 March 2003

References
6 Graham DA, Kinyoun JL, George DP. Ocular hypotensive agents, and in two cases oral azole. In all cases an open sclerectomy was confirmed by gonioscopy.

All procedures were performed in the outpatient clinic, by either a consultant or associate specialist, using a slit lamp. The eye was anaesthetised with amethocaine eye drops 1%, and phenylephrine eye drops 2.5% were used for vasoconstriction. After several drops of chloramphenicol the conjunctiva was entered several millimetres from the flap site with a 27 gauge needle mounted on an insulin syringe. In one case aqueous flow was established after perforating scar tissue around an encysted bleb, whereas in the others it was necessary to dissect beneath the scleral flap and enter the anterior chamber. After creating a bleb and confirming a reduction in IOP by applanation tonometry, 5 mg 5-FU (25 mg/ml) were injected into the subconjunctival space around the bleb. After needling, all hypotensive therapies were stopped and replaced by intensive topical steroids and chloramphenicol. The scleral flap was dissected, and repeated injections of 5-FU with or without needling were given, according to the IOP and appearance of the bleb. After 12 months follow up from the last needling (Table 2), average IOP was reduced to 14 mm Hg (range 9–17). There was no change in the patients’ visual acuity. Two cases developed a mild corneal epitheliopathy that healed within 8 weeks. There were no other complications from the needleling procedure.

Case reports

The demographic details of all cases are summarised in Table 1.

Glucoma surgery had taken place between 8 and 31 years before bleb needling and in no case had antimiotics been used after the original surgery. Before bleb needling the average intraocular pressure (IOP) among the patients was 29.4 mm Hg (range 19–58). Each patient showed glaucomatous deterioration despite being on maximum tolerated medical therapy, taking on average three ocular hypertensive agents, and in two cases oral azole. In all cases an open sclerectomy was confirmed by gonioscopy.

Table 1 Demographic details of patients

<table>
<thead>
<tr>
<th>Case no</th>
<th>Drainage procedure</th>
<th>Delay to needling (years)</th>
<th>No of needlings</th>
<th>No of 5-FU injections</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M Bilateral Schein’s</td>
<td>31</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>2</td>
<td>F Left ECCE-trabeculectomy</td>
<td>10</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>3</td>
<td>F Right trabeculectomy</td>
<td>12</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>4</td>
<td>F Right trabeculectomy</td>
<td>8</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>5</td>
<td>M Bilateral trabeculectomy</td>
<td>13</td>
<td>1</td>
<td>2</td>
</tr>
</tbody>
</table>

ECCE = extracapsular cataract surgery.

Table 2 Results of pre-bleb and post-bleb needling with a 12 month follow up period

<table>
<thead>
<tr>
<th>Case no</th>
<th>Age (years)</th>
<th>Sex</th>
<th>Pre</th>
<th>Post</th>
<th>No of medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>72</td>
<td>M</td>
<td>19</td>
<td>9</td>
<td>3+ acetazolamide</td>
</tr>
<tr>
<td>2</td>
<td>88</td>
<td>F</td>
<td>25</td>
<td>14</td>
<td>3 acetazolamide</td>
</tr>
<tr>
<td>3</td>
<td>80</td>
<td>F</td>
<td>20</td>
<td>17</td>
<td>2 acetazolamide</td>
</tr>
<tr>
<td>4</td>
<td>35</td>
<td>M</td>
<td>58</td>
<td>12</td>
<td>3 acetazolamide</td>
</tr>
<tr>
<td>5</td>
<td>71</td>
<td>M</td>
<td>25</td>
<td>16</td>
<td>2 acetazolamide</td>
</tr>
</tbody>
</table>

Comment

Although trabeculectomy is the preferred glaucoma drainage procedure, only 67% of patients may achieve an adequate target pressure after 1 year. In recent years glaucoma surgery has developed with the use of antimiotics and intense postoperative surveillance with bleb manipulation. Reports show that bleb needling used in combination with subconjunctival 5-FU injections can rectify a failing bleb in the early postoperative phase but there are few reports confirming its effect in the late postoperative period. Some studies have indicated that the success of bleb needling is unrelated to the time lapsed from the original surgery, though in these studies the maximum interval period was less than 4.5 years. The patients presented in this study had had their original glaucoma surgery at least 8 years previously and bleb needling was carried out before listing the patient for a repeat trabeculectomy with mitomycin C. The only adverse effect noted was a temporary corneal epitheliopathy, probably related to toxicity of the 5-FU. Other reported adverse events after bleb needling include hyphaema, bleb leak, shallow anterior chamber, choroidal effusion and endophthalmitis, but there are no reports of long term hypotony as has been described following mitomycin C trabeculectomy.

These case reports indicate that bleb needling may be successful in achieving a long lasting IOP reduction even several years after the original surgery. The procedure does not require dextros skills beyond that of a trained general ophthalmologist. It appears at least as safe as trabeculectomy and avoids a formal operation. If it does fail the surgical field is still intact for a “redo” trabeculectomy.

C T Ung, H Von Lany, K G Claridge
Taunton and Somerset NHS Trust, Musgrove Park, Taunton TA1 5DA, UK
Correspondence to: Ms Katherine Claridge, Taunton and Somerset NHS Trust, Musgrove Park, Taunton TA1 5DA, UK, kite.claridge@nhs.uk

Accepted for publication 31 March 2003

References

MAILBOX

The success rates for endonasal dacryocystorhinostomy

Tirbas and Wormald are to be congratulated on their landmark paper in lacrimal surgery describing endonasal dacryocystorhinostomy (DCR) with mucosal flaps, which is also known as powered endonasal DCR.¹ Their results are seemingly impressive, with anatomical success rate of 95% and functional success rate of 89%, closely approaching those of other endonasal DCR techniques. However, their success rates for mechanical endonasal DCR reported by Tirbas and Wormald¹ appear to be very good (95% anatomical and 89% functional success), but their follow up period varied from only 2 months on one flap group to a minimum 6 months on the other group. Most of the patients who had only a short follow up time may subsequently fail. A paper published in the American Journal of Ophthalmology by the same authors using the same technique,¹ where they had a minimal follow up of 9 months, had a lower anatomical success rate (91%).

It is important to define success and what this really means, and for lacrimal surgeons to agree consistent outcome criteria. Perhaps lacrimal surgeons should agree the following criteria for DCR surgical success, irrespective of whether it is by an external or endonasal route:

- Assess the outcome a minimum of 6 months after surgery, being at least 3 months after removal of tubes. Or is 1 year after surgery better?
- Assess subjective success based on the patient’s symptoms.
- Assess objective success (anatomical success) based on (i) patency on syringing and (ii) presence of a functioning rhinostomy.
- The latter is evaluated using the functional endoscopic dye test, which is positive when 2% fluorescein instilled in the conjunctival fornix is seen emerging from the rhinostomy a few seconds later.²³

Despite these minor quibbles, the authors are to be congratulated on advancing endonasal lacrimal surgery.

J M Oliver
Western Eye Hospital, Marylebone Road, London NW1 5YE, UK
janeoliver@aol.com
Accepted of publication 11 February 2003

References

Trypan blue stains the epiretinal membrane but not the internal limiting membrane

We read with great interest the paper by Li et al about staining of the internal limiting membrane (ILM) and epiretinal membrane (ERM) with trypan blue (TB).¹ We would like to comment on one aspect of this paper, when the authors claimed that a good staining of both the ILM and the ERM was achieved with TB. We disagree that ILM is stained by TB, and propose that TB only stains the ERM, not the ILM.

The authors affirm “ILM staining” with TB as they observed histologically the presence of ILM in four eyes with macular holes at stage III and IV. In one of those eyes, immunohistochemistry was performed, and an epiretinal membrane was observed. In the other three cases, immunohistochemistry examination was not performed because of insufficient tissue. Most of the stage III and IV macular holes are known to be associated with an epiretinal membrane,¹ and probably an ILM would be seen in addition to the ILM in those three cases if immunohistochemistry for glial elements were performed. Therefore, we believe that TB stained the ERM associated with the macular holes, but not the ILM. In their study, staining with TB of seven patients with idiopathic epiretinal membrane was successfully performed. ERM of proliferative vitreoretinopathy is also reported to be well stained by TB.¹ We speculate that TB has binding affinity to some of the glial cell elements of the highly cellular ERM, either those associated with macular holes or not.

Indocyanine green (ICG) is another dye for intraretinal staining that has wide acceptance among retina surgeons in the past few years.²⁻⁴ In contrast with the cellular affinity of TB, ICG stains the acellular ILM, because of the fast binding of ICG to collagen proteins of the ILM. ERM tends to be stained negatively by ICG, well because the hydrophilic ICG does not penetrate cell membranes easily.¹

TB staining seems to be a good alternative to ICG staining in the surgical management of macular diseases. Further studies are warranted on the intraretinal kinetics of that dye.

E B Rodrigues, C H Meyer, J C Schmidt, P Kroll
Department of Ophthalmology, Philipps-University Marburg, Germany
Correspondence to: E B Rodrigues, MD; Department of Ophthalmology, Philipps-University Marburg, Germany, edubrodriques@yahoo.com.br

Accepted for publication 4 April 2003

References
1. Li K, Wong D, Hiscott P, et al. Trypan blue staining of internal limiting membrane and...
Thermochemotherapy in hereditary retinoblastoma

Schueler and associates describe their experience with thermochemotherapy (TCT) in bilateral retinoblastoma. The reported results of transpupillary thermotherapy used in combination with chemotherapy are encouraging, with 86–96% tumour control.

In the current series, however, local recurrence occurred in 38%.

The dosages of carboplatin used in the current series was 10 mg/kg body weight, which is lower than the standard dosage of 18.6 mg/kg body weight. Lower dose of carboplatin, the key drug in the chemotherapy regimen for retinoblastoma, could have influenced the higher recurrence rate.

The authors mention that they treated submacular tumours with TCT. However, in our experience, tumours located in the macular area are better treated initially with chemotherapy for 3–6 cycles in order to achieve maximum possible reduction in tumour size before considering thermotherapy. Chemotherapy reduced macular tumours tend to shrink away from the fovea towards one of the major arcades or the optic nerve, thus exposing the foveal region. Tumours located beyond 3–6 cycles of chemotherapy could be treated with thermotherapy. A smaller scar thus produced may optimise residual central vision.

The high mean total duration of thermochemotherapy in the current series is probably because of a smaller spot size of 0.4 mm. The diode laser (Iris Medical Inc, Mountain View, CA, USA) with an operating microscope adapter allows for a spot size of 0.8, 1.2, and 2.0 mm. The relatively newer large spot indirect ophthalmoscope delivery system provides a 1.2 mm spot size. A larger spot size will indeed reduce the duration of thermotherapy and allow for a more uniform coverage. Corneal, iris, and lens complications are minimised with better convergent beam optical systems currently available.

We believe that with higher dose of carboplatin, staggered thermotherapy for submacular tumours, use of better optical systems for delivery and a larger spot size for thermotherapy, and judicious selection of cases, the tumour regression and vision salvage with TCT could be further optimised.

R Murthy, S G Honavar, M Naik, V A P Reddy
Ocular Oncology Service, LV Prasad Eye Institute, Hyderabad, India

Correspondence to: Santosh G Honavar, MD, Ocular Oncology Service, LV Prasad Eye Institute, LV Prasad Marg, Banjara Hills, Hyderabad 500 034, India; honavar@lpeye.sph.net

Accepted for publication 21 April 2003

References


CORRECTIONS

An error occurred in the author listings for two letters in the September issue. In the letter by Lee et al (Br J Ophthalmol 2003;87:1184–5) the order should be D K Lee, E B Suhler, W Augustin, R R Buggage.

In the letter by Buggage et al (Br J Ophthalmol 2003;87:1190–1) the order should be R R Buggage, D G Callanan, D F Shen, C-C Chen. The journal apologises for the error.

In the article by Williamson et al in the September issue (Br J Ophthalmol 2003;87:1126–9), the author list contained an error. The correct spelling is N Strotzidis. The journal apologises for the error.

In the article by Courtright et al in the September issue (Br J Ophthalmol 2003;87:1079–82), the author list contained an error. The correct spelling is A Hroechnsam. The journal apologises for the error.
**NOTICES**

**Elimination of avoidable blindness**

The latest issue of Community Eye Health (No 46) discusses the resolution of the World Health assembly on the elimination of avoidable blindness. For further information please contact: Journal of Community Eye Health, International Resource Centre, International Centre for Eye Health, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, email: tel:+44 (0)1803 44 4134; email: Anita.Shabh@lshtm.ac.uk; website: www.jceh.co.uk). Annual subscription (4 issues) UK £28/US$45. Free to developing country applicants.

**Second sight**

Second Sight, a UK based charity whose aims are to eliminate the backlog of cataract blind in India by the year 2020 and to establish strong links between Indian and British ophthalmologists is regularly sending volunteer surgeons to India. Details can be found at the charity’s website (www.secondsight.org.uk) or by contacting Dr Lucy Mathen (lucymathen@yahoo.com).

**Specific Eye Conditions (SPECs)**

SPECs represents over 50 different organisations related to eye disorders ranging from conditions that are relatively common to very rare syndromes. The website acts as a portal giving direct access to support groups’ own websites. The SPECs web page is a valuable resource for professionals and may also be of interest to people with a visual impairment or who are blind. For further details about SPECs, contact: Kay Parkinson, SPECs Development Officer (tel: +44 (0)1803 524238; email: k@eyeconditions.org.uk; website: www.eyeconditions.org.uk).

**The British Retinitis Pigmentosa Society**

The British Retinitis Pigmentosa Society (BRPS) was formed in 1975 to bring together people with retinitis pigmentosa and their families. The principle aims of BRPS are to raise funds to support the programme of medical research into an early clinical cure for this hereditary disease, and through the BRPS welfare service, help members and their families cope with the everyday consequences caused by retinitis pigmentosa. Part of the welfare service is the telephone help line (+44 (0)1280 860 363) for any queries relating to retinitis pigmentosa, especially for those recently diagnosed with retinitis pigmentosa (tel: +44 (0)1280 821 314; email: lynda@brps.demon.co.uk; website: www.brps.demon.co.uk).

**Surgical Eye Expeditions International**

Volunteer ophthalmologists in active surgical practice are needed to participate in short term, sight restoring eye surgery clinics around the world. Contact: Harry S Brown, Surgical Eye Expeditions International, 27 East De La Guerra, C-2, Santa Barbara, CA 93101-9858, USA (tel: +805 963 3303; fax: +805 965 3564; email: hsbrown.md@cox.net or seeintl@seeintl.org; website: www.seeintl.org).

**Rise in organ transplant numbers**

According to UK Transplant, the UK has seen the highest number of organ transplants in six years. Last year (1 April 2002 to 31 March 2003), 2777 patients had their lives saved or dramatically improved through the generosity of 1064 donors. This equated to a 6% increase compared to the previous 12 months (1 April 2001 to 31 March 2002). Furthermore, during 2002–3, the highest number of people benefited from a cornea transplant for five years (1997–98) and 240 more people had their sight restored than the previous year. For further information see UK Transplant’s website (www.uktransplant.org.uk).

**Elimination of avoidable blindness**

The 56th World Health Assembly (WHA) considered the report on the elimination of avoidable blindness (doc A56/26) and urged Member States to: (1) Commit themselves to supporting the Global Initiative for the Elimination of Avoidable Blindness by setting up a national Vision 2020 plan by 2005; (2) Establish a national coordinating committee for Vision 2020; (3) Establish a national blindness prevention committee to help implement the plan; (3) Implement the plan by 2007; (4) Include effective monitoring and evaluation of the plan with the aim of showing a reduction in the magnitude of avoidable blindness by 2010; (5) To support the mobilisation of resources for eliminating avoidable blindness. The WHA also urged the Director-General to maintain and strengthen WHO’s collaboration with Member States and the partners of the Global Initiative for the Elimination of Avoidable Blindness as well as aid in the coordination and support of national capability.

**Glaucoma Society 24th Annual Meeting and Dinner**

The Glaucoma Society 24th Annual Meeting and Dinner will take place on 20 November 2003, from 8:30 am to 3:00 pm at The Royal College of Physicians, London, UK. Further details: Ms Janet Flowers (email: glausoc@ukeire.freeserve.co.uk).

**Detachment course with international faculty on: retinal and vitreous surgery with case presentations preceding the annual meeting of Iranian Society of Ophthalmology**

The detachment course with international faculty on: Retinal and Vitreous Surgery with Case Presentations preceding the Annual Meeting of the Iranian Society of Ophthalmology will be held on 29-30 November 2003 and 1-4 December 2003 respectively, at the Razi Conference Center, Hemmat Hyw, Tehran, Iran. Further details: Scientific programme: Prof Ingrid Kreyssig, University of Tuebingen, Schleichstr. 12, Breuningenbau, 72076 Tuebingen, Germany (tel: +49 7071 295209; email: ingrid.kreissig@med.uni-tuebingen.de). Local organisation: Dr Arman Masheyekhi, Dr Siamak Moradian, Dept of Ophthalmology, Labbanfinejad Medical Center, Pasdaran Ave, Boostan 9, Tehran, 16666, Iran (fax: +98 21 254 9039; email: labbali@hotmail.com).

**5th International Symposium on Ocular Pharmacology and Therapeutics (ISOPT)**

The 5th International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) will take place 11-14 March 2004, in Monte Carlo, Monaco. Please visit our website for details of the scientific programme, registration, and accommodation. To receive a copy of the Call for Abstracts and registration brochure, please submit your full mailing details to http://www.kenes.com/isopt/interest.htm. Further details: ISOPT Secretariat (website: www.kenes.com/isopt).

**XVth Meeting of the International Neuro-Ophthalmology Society**

The XVth Meeting of the International Neuro-Ophthalmology Society will take place 18-22 July 2004, in Geneva, Switzerland. Further details: Prof. A Safran, University Hospital Geneve, c/o SYMPORG SA, Geneva (fax: +4122 839 8484; email: info@symorg.ch; website: www.symorg.ch).

**4th International Congress on Autoimmunity**

The 4th International Congress on Autoimmunity will take place 3–7 November 2004 in Budapest, Hungary. The deadline for the receipt of abstracts is 20 June 2004. Further details: Kened International Global Congress Organisers and Association Management Services, 17 Rue du Cendrier, PO Box 1726, CH-1211 Geneva 1, Switzerland (tel: +41 22 908 0488; fax: +41 22 732 2850; email: autoim04@keneds.com; website: www. keneds.com/autoim2004).

**Wake up call as dream time deadline looms**

Scientists have less than a month left to apply for a new Dream Time award from NESTA, the organisation that invests in UK creativity and innovation. Dream Time supports exceptional achievers (with at least 10 years experience in their field) who want time to experiment or follow a passion, but who want to continue with their career and put what they have discovered to good use. Up to 12 exceptional individuals from the fields of science, technology and the arts each will receive up to £40,000 to pursue their goals and push at the boundaries of knowledge and practice. NESTA is looking for people who can demonstrate evidence of exceptional achievement. This would include a significant body of work collated over at least a decade in their field, the ability to work in new ways and a commitment to the proposed area of exploration. Dream Time is a development of NESTA’s existing Fellowship Programme, which has helped talented and creative individuals to innovate and explore new ideas emerging through periods of personal development. As with all its awards, NESTA is looking for people who demonstrate excellence, promise, creativity, innovation and commitment. Funding can be used on a full- or part-time basis, in tandem with professional careers or temporarily away from the constraints of employment. Offered awards can be for any period of time up to
one year. Dream Time Fellows will be asked to provide 10% in kind support for their plan and will be required to plan ways of disseminating their findings with their professional community. To apply, visit NESTA’s website: www.nesta.org.uk/dreamtime.

14th Meeting of the EASD Eye Complication study group

The 14th Meeting of the EASD Eye Complication (EASDEC) study group will take place on the 21–23 May 2004. There will be key lecture notes on the following topics: Peter Gaede (Denmark)–Results of the Steno 2 study, Hans Peter Hammes (Germany)–Animal models of diabetic retinopathy, Massimo Porta (Italy)–Screening with the London protocols: 12 years after, and Anselm Kampik (Germany)–Surgical options in diabetic retinopathy. There will also be case presentations and oral and poster presentations. The EASDEC board comprises F Bandello (President), PJ Guillausseau (Vice President), C-D Agardh (Past President), P Massin (Secretary), M Porta (Treasurer). The Scientific and Organizing Committee includes: F Bandello, PJ Guillausseau, P Massin, C-D Agardh, M Porta, A Kampik, M Ulbig, and G Lang. There are three travel grants available, at 1000 Euro each, for young scientists (less than 35 years at the time of the meeting). Application for the grant should be made together with the submission of the abstract. For further information, contact: Department of Ophthalmology, Ingrid Mannl, Ludwig-Maximilians-University, Mathildenstr. 8, 80336 Munich, Germany (tel: +49–89–5160–3800; fax: +49 89 5160 4778; e-mail: easdec@ak-i.med.uni-muenchen.de. The deadline for abstracts is 2 March 2004.